Search - tctmd.com

Displaying 321 - 340 of 371

Sort: Relevancy | Date

Indian TUXEDO Trial In Medically Treated Diabetics

Presentation TCTAP 2012

Indian TUXEDO Trial In Medically Treated Diabetics

Presenter: Upendra Kaul

April 26, 2012

News Daily News

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

April 25, 2012

News Daily News

Meta Análisis: Los SLF de 1ª Generación se Muestran Seguros y Eficaces a Largo Plazo contra los STEMI

April 25, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

March 24, 2012

News Daily News

La Depresión tras una PCI se asocia a Mortalidad a Largo Plazo

Yael L. Maxwell

March 21, 2012

News Daily News

Depression After PCI Linked to Long-term Mortality

Yael L. Maxwell

March 21, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

March 06, 2012

News Daily News

El Estudio no Halla “Paradoja de la Obesidad” alguna en Pacientes Tratados con SLF

March 06, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

February 20, 2012

News Daily News

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Yael L. Maxwell

February 15, 2012

News Daily News

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

January 08, 2012

News Daily News

Clopidogrel Prescriptions Not Being Filled Fast Enough, If at All

Yael L. Maxwell

December 14, 2011

News Conference News

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

November 30, 2011

News Conference News

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

November 17, 2011

News Conference News

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

November 16, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Daily News

DES Associated with Less Downstream Lesion Development than BMS

November 04, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.